

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:esptasxsl626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT 02	CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	3	OCT 19	BEILSTEIN updated with new compounds
NEWS	4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	5	NOV 19	WPIX enhanced with XML display format
NEWS	6	NOV 30	ICSD reloaded with enhancements
NEWS	7	DEC 04	LINPADOCDB now available on STN
NEWS	8	DEC 14	BEILSTEIN pricing structure to change
NEWS	9	DEC 17	USPATOLD added to additional database clusters
NEWS	10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	11	DEC 17	DGENE now includes more than 10 million sequences
NEWS	12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	14	DEC 17	CA/Caplus enhanced with new custom IPC display formats
NEWS	15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	16	JAN 02	STN pricing information for 2008 now available
NEWS	17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	19	JAN 28	MARPAT searching enhanced
NEWS	20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	23	FEB 08	STN Express, Version 8.3, now available
NEWS	24	FEB 20	PCI now available as a replacement to DPCI
NEWS	25	FEB 25	IFIREF reloaded with enhancements
NEWS	26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	28	MAR 31	IFICDB, IFIPAT, and IFIUDS enhanced with new custom IPC display formats
NEWS	29	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	30	MAR 31	CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS	31	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	32	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:14:25 ON 01 APR 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:14:43 ON 01 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAR 2008 HIGHEST RN 1011196-35-2
DICTIONARY FILE UPDATES: 31 MAR 2008 HIGHEST RN 1011196-35-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>
Uploading C:\Documents and Settings\sshterengarts\My Documents\Sam's Documents\STN STRUCTURES\10552575.str



```

chain nodes :
5 6 7 9 10 23
ring nodes :
1 2 3 4 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
2-9 4-5 5-6 5-7 6-23 9-10 10-11 10-12
ring bonds :
1-2 1-4 2-3 3-4 11-13 11-17 12-18 12-22 13-14 14-15 15-16 16-17 18-19
19-20 20-21 21-22
exact/norm bonds :
1-2 1-4 2-3 2-9 3-4 4-5 5-6 5-7 6-23 9-10
exact bonds :
10-11 10-12
normalized bonds :
11-13 11-17 12-18 12-22 13-14 14-15 15-16 16-17 18-19 19-20 20-21 21-22

```

G1:Ak,H

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:CLASS 7:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Ak,H

Structure attributes must be viewed using SIN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 18:15:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      13 TO ITERATE

100.0% PROCESSED      13 ITERATIONS      3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   44 TO    476
PROJECTED ANSWERS:      3 TO    163

L2          3 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 18:15:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      268 TO ITERATE

100.0% PROCESSED      268 ITERATIONS      135 ANSWERS
SEARCH TIME: 00.00.01

L3          135 SEA SSS FUL L1

=> s l1 exact full
FULL SEARCH INITIATED 18:15:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      32 TO ITERATE

100.0% PROCESSED      32 ITERATIONS      0 ANSWERS
SEARCH TIME: 00.00.01

L4          0 SEA EXA FUL L1

=> s l1 fam full
FULL SEARCH INITIATED 18:15:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      46 TO ITERATE

100.0% PROCESSED      46 ITERATIONS      0 ANSWERS
SEARCH TIME: 00.00.01

L5          0 SEA FAM FUL L1
```

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	308.32	308.53

FILE 'CAPLUS' ENTERED AT 18:15:50 ON 01 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Apr 2008 VOL 148 ISS 14
FILE LAST UPDATED: 31 Mar 2008 (20080331/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 18:14:25 ON 01 APR 2008)

FILE 'REGISTRY' ENTERED AT 18:14:43 ON 01 APR 2008

L1	STRUCTURE UPLOADED
L2	3 S L1
L3	135 S L1 SSS FULL
L4	0 S L1 EXACT FULL
L5	0 S L1 FAM FULL

FILE 'CAPLUS' ENTERED AT 18:15:50 ON 01 APR 2008

=> s l3

L6 5 L3

=> d l6 1-5 ibib abs hitstr

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:965242 CAPLUS

DOCUMENT NUMBER: 141:410806

TITLE: Preparation of azetidinecarboxamide derivatives and analogs for the treatment of CB1 receptor-mediated disorders

INVENTOR(S): Davidson, James Edward Paul; Bentley, Jonathan Mark; Dawson, Claire Elizabeth; Harrison, Kerry; Mansell, Howard Langham; Pither, Alan Leslie; Pratt, Robert Mark; Roffey, Jonathan Richard Anthony; Ruston, Victoria Jane



PATENT ASSIGNEE(S): Vernalis Research Limited, UK

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096794	A1	20041111	WO 2004-GB1884	20040429
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1618105	A1	20060125	EP 2004-730303	20040429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006525299	T	20061109	JP 2006-506208	20040429
US 20070173486	A1	20070726	US 2005-554447	20051025
PRIORITY APPLN. INFO.:			GB 2003-10052	A 20030501
			WO 2004-GB1884	W 20040429
OTHER SOURCE(S):		MARPAT 141:410806		
GI				



AB Title compds. I [wherein R1 = (hetero)aryl; R2 = alkyl or (hetero)aryl; R3 = alkyl, (hetero)aryl, substituted amino, alkoxy or amide; R11, R12 = H or alkyl; Y = C(O), C(S), SO2, or alkylene; m = 1 or 2; n = 1 or 2; with some limitations, and pharmaceutically acceptable salts or prodrugs thereof], useful for the treatment of CB1 receptor-mediated disorders, such as obesity, were prepared Compds. I were tested in several biol. assays, and six compds. were reported to have binding constant Ki values from 0.8 to 27.7 nM against recombinant human CB1 (hCB1) receptor. For example, azetidinecarboxamide II was synthesized in several steps, and had Ki value of 0.8 nM against hCB1 receptor.

IT 791119-25-0P 791119-28-3P, 3-[[2-(Trifluoromethyl)-4'-

fluorobenzhydryl]oxy]-N-(benzoyl)azetidine-1-carboxamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of azetidinecarboxamide derivs. and analogs for treatment of CB1 receptor mediated disorders)

RN 791119-25-0 CAPLUS


CN L-Phenylalanine, N-[[3-[(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-1-azetidinyl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 791119-28-3 CAPLUS

CN 1-Azetidinecarboxamide, N-benzoyl-3-[(4-fluorophenyl)[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:965215 CAPLUS

DOCUMENT NUMBER: 141:410805

TITLE: Preparation of azetidinecarboxamide derivatives for

the treatment of CB1 receptor-mediated disorders
INVENTOR(S): Davidson, James Edward Paul; Dawson, Claire Elizabeth;
Harrison, Kerry; Mansell, Howard Langham; Pratt,
Robert Mark; Sohal, Suhkjit; Ruston, Victoria Jane

PATENT ASSIGNEE(S): Vernalis Research Limited, UK

SOURCE: PCT Int. Appl., 101 pp.


DOCUMENT TYPE: CODEN: PIXXD2

Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096763	A1	20041111	WO 2004-GB1831	20040429
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004234125	A1	20041111	AU 2004-234125	20040429
CA 2524251	A1	20041111	CA 2004-2524251	20040429
EP 1620395	A1	20060201	EP 2004-730296	20040429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009938	A	20060425	BR 2004-9938	20040429
CN 1802350	A	20060712	CN 2004-80011598	20040429
JP 2006525298	T	20061109	JP 2006-506198	20040429
MX 2005PA11670	A	20051215	MX 2005-PA11670	20051028
NO 2005005654	A	20060131	NO 2005-5654	20051130
IN 2005CN03221	A	20070914	IN 2005-CN3221	20051201
US 20070054891	A1	20070308	US 2006-552575	20060804
PRIORITY APPLN. INFO.:			GB 2003-10056	A 20030501
			WO 2004-GB1831	W 20040429


OTHER SOURCE(S): MARPAT 141:410805
 GI




AB Title compds. I [wherein R1, R2 = aryl; R3 = H or alkyl; with some limitations, and pharmaceutically acceptable salts or prodrugs thereof], useful for the treatment of CB1 receptor-mediated disorders, such as obesity, were prepared. For example, 1-benzhydryl-3-azetidinoxy was coupled with 2,4,4'-trichlorobenzhydryl (50%) followed by deprotection of N-benzhydryl group (60%) gave 3-(2,4,4'-trichlorobenzhydryloxy)azetidine. This compound underwent addition reaction with tert-Bu isocyanate yielded azetidinecarboxamide II (78%). Compds. II were found (1) to bind to the recombinant human CB1 (hCB1) receptor with a Ki value of 4.7 nM; (2) to antagonize the reduction in the locomotor behavior with a value of 30, p.o. (active dose (mg/kg), route); and (3) to regulate feeding behavior with a

value of 30, p.o. (M.E.D (mg/kg), route).


- IT 791847-89-7P, 3-[[2-(Trifluoromethyl)-4'-chlorobenzhydryl]oxy]-N-(tert-butyl)azetidine-1-carboxamide 791848-05-0P, 3-[[2-(Trifluoromethyl)-2'-fluoro-4'-bromobenzhydryl]oxy]-N-(tert-butyl)azetidine-1-carboxamide 791848-90-3P, 3-[[2-(Trifluoromethyl)phenyl][4'-(methoxycarbonyl)phenyl]methoxy]-N-tert-butylazetidine-1-carboxamide
- RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
- (drug candidate; preparation of azetidinecarboxamide derivs. for the treatment of CB1 receptor-mediated disorders)
- RN 791847-89-7 CAPLUS
- CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



- RN 791848-05-0 CAPLUS
- CN 1-Azetidinecarboxamide, 3-[(4-bromo-2-fluorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



- RN 791848-90-3 CAPLUS
- CN Benzoic acid, 4-[[[1-[[[(1,1-dimethylethyl)amino]carbonyl]-3-azetidinyl]oxy]2-(trifluoromethyl)phenyl]methyl]-, methyl ester (CA INDEX NAME)



IT 791847-07-9P, 3-(2,4,4'-Trichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide 791847-08-0P, 3-(2,4,4'-Trichlorobenzhydryloxy)-N-(1-hydroxy-2-methylpropan-2-yl)azetidine-1-carboxamide 791847-09-1P 791847-10-4P, 3-(2,4'-Dichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide 791847-11-5P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[2-(thiophen-2-yl)ethyl]azetidine-1-carboxamide 791847-12-6P 791847-13-7P 791847-14-8P, 3-(2,4'-Dichlorobenzhydryloxy)-N-(cyclopropylmethyl)azetidine-1-carboxamide 791847-15-9P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[(2,3-dihydrobenzofuran-5-yl)methyl]azetidine-1-carboxamide 791847-16-0P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[(2,5-dimethylfuran-3-yl)methyl]azetidine-1-carboxamide 791847-17-1P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[(2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]azetidine-1-carboxamide 791847-18-2P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[(5-methylisoxazol-3-yl)methyl]azetidine-1-carboxamide 791847-19-3P 791847-20-6P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[(2-bromothiophen-3-yl)methyl]azetidine-1-carboxamide 791847-21-7P 791847-22-8P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[(thiophen-3-yl)methyl]azetidine-1-carboxamide 791847-23-9P, 3-(2,4'-Dichlorobenzhydryloxy)-N-(2-methoxyphenylmethyl)azetidine-1-carboxamide 791847-24-0P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[(2-furanyl)methyl]azetidine-1-carboxamide 791847-25-1P, 3-(2,4'-Dichlorobenzhydryloxy)-N-(3-ethoxypropyl)azetidine-1-carboxamide 791847-26-2P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[(tetrahydrofuran-2-yl)methyl]azetidine-1-carboxamide 791847-27-3P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[3-(2-oxopyrrolidinyl)propyl]azetidine-1-carboxamide 791847-29-5P, 3-(2,4'-Dichlorobenzhydryloxy)-N-(1-phenylpropyl)azetidine-1-carboxamide 791847-30-8P 791847-31-9P 791847-32-0P, 3-(2,4'-Dichlorobenzhydryloxy)-N-[2-(dimethylamino)ethyl]azetidine-1-carboxamide 791847-33-1P 791847-34-2P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide 791847-35-3P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(hexyl)azetidine-1-carboxamide 791847-38-6P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(3-methylbenzyl)azetidine-1-carboxamide 791847-39-7P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(4-methylbenzyl)azetidine-1-carboxamide 791847-40-0P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(2,4-dichlorobenzyl)azetidine-1-carboxamide 791847-41-1P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(phenethyl)azetidine-1-carboxamide 791847-42-2P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(4-fluorobenzyl)azetidine-1-carboxamide 791847-43-3P 791847-44-4P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(4-methoxybenzyl)azetidine-1-carboxamide 791847-45-5P

791847-46-6P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(cyclopropylmethyl)azetidine-1-carboxamide 791847-47-7P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(benzhydryl)azetidine-1-carboxamide 791847-49-9P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(cyclohexylmethyl)azetidine-1-carboxamide 791847-50-2P, 3-(4,4'-Dichlorobenzhydryloxy)-N-[(thiophen-2-yl)methyl]azetidine-1-carboxamide 791847-51-3P, 3-(4,4'-Dichlorobenzhydryloxy)-N-[(6-Fluoro-4H-benzo[1,3]dioxin-8-yl)methyl]azetidine-1-carboxamide 791847-52-4P, 3-(4,4'-Dichlorobenzhydryloxy)-N-[(2,3-dihydrobenzofuran-5-yl)methyl]azetidine-1-carboxamide 791847-53-5P, 3-(4,4'-Dichlorobenzhydryloxy)-N-(benzodioxol-5-yl)methyl]azetidine-1-carboxamide 791847-54-6P, 3-(4,4'-Dichlorobenzhydryloxy)-N-[(2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]azetidine-1-carboxamide 791847-55-7P, 3-(4,4'-Dichlorobenzhydryloxy)-N-[[2-(thiophen-2-yl)thiazol-4-yl)methyl]azetidine-1-carboxamide 791847-56-8P, 3-(4,4'-Dichlorobenzhydryloxy)-N-[(benzo[b]thiophen-3-yl)methyl]azetidine-1-carboxamide 791847-57-9P, 3-(4,4'-Dichlorobenzhydryloxy)-N-[(thiophen-3-yl)methyl]azetidine-1-carboxamide 791847-58-0P, 3-(4,4'-Dichlorobenzhydryloxy)-N-[(5-methylisoxazol-3-yl)methyl]azetidine-1-carboxamide 791847-59-1P, 3-(4,4'-Dichlorobenzhydryloxy)-N-[(benzo[b]thiophen-2-yl)methyl]azetidine-1-carboxamide 791847-63-7P, 3-(2,2'-Dichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide 791847-64-8P, 3-(2,2'-Dichlorobenzhydryloxy)-N-(isopropyl)azetidine-1-carboxamide 791847-65-9P, 3-(2,2'-Dichlorobenzhydryloxy)-N-(sec-butyl)azetidine-1-carboxamide 791847-66-0P, 3-(2,2'-Dichlorobenzhydryloxy)-N-propylazetidine-1-carboxamide 791847-67-1P, 3-(2,2'-Dichlorobenzhydryloxy)-N-(allyl)azetidine-1-carboxamide 791847-68-2P, 3-(2,2'-Dichlorobenzhydryloxy)-N-butylazetidine-1-carboxamide 791847-71-7P, 3-(2,2'-Dichlorobenzhydryloxy)-N-(phenethyl)azetidine-1-carboxamide 791847-73-9P, 3-(2,2'-Dichlorobenzhydryloxy)-N-[(6-Fluoro-4H-benzo[1,3]dioxin-8-yl)methyl]azetidine-1-carboxamide 791847-74-0P, 3-(2,2'-Dichlorobenzhydryloxy)-N-[2-(1-piperidyl)benzyl]azetidine-1-carboxamide 791847-76-2P, 3-(2,2'-Dichlorobenzhydryloxy)-N-(cyclohexylmethyl)azetidine-1-carboxamide 791847-77-3P, 3-(2,2'-Dichlorobenzhydryloxy)-N-[(benzo[b]thiophen-3-yl)methyl]azetidine-1-carboxamide 791847-80-8P, 3-(4,4'-Dibromobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide 791847-81-9P, 3-(4,4'-Dibromobenzhydryloxy)-N-(isopropyl)azetidine-1-carboxamide 791847-82-0P, 3-(4,4'-Dibromobenzhydryloxy)-N-(isobutyl)azetidine-1-carboxamide 791847-83-1P, 3-(4,4'-Dibromobenzhydryloxy)-N-propylazetidine-1-carboxamide 791847-84-2P, 3-(4,4'-Dibromobenzhydryloxy)-N-butylazetidine-1-carboxamide 791847-87-5P, 3-(4,4'-Dibromobenzhydryloxy)-N-(phenethyl)azetidine-1-carboxamide 791847-90-0P, 3-[[2-(Trifluoromethyl)-4'-chlorobenzhydryl]oxy]-N-propylazetidine-1-carboxamide 791847-91-1P, 3-[[2-(Trifluoromethyl)-4'-chlorobenzhydryl]oxy]-N-(isopropyl)azetidine-1-carboxamide 791847-92-2P, 3-[[2-(Trifluoromethyl)-4'-chlorobenzhydryl]oxy]-N-butylazetidine-1-carboxamide 791847-93-3P, 3-[[2-(Trifluoromethyl)-4'-chlorobenzhydryl]oxy]-N-(sec-butyl)azetidine-1-carboxamide 791847-94-4P 791847-96-6P, 3-[[2-(Trifluoromethyl)-4'-chlorobenzhydryl]oxy]-N-(ethyl)azetidine-1-carboxamide 791847-97-7P 791847-98-8P, 3-[[2-(Trifluoromethyl)-4'-chlorobenzhydryl]oxy]-N-(2,2,4-trimethylpentan-4-yl)azetidine-1-carboxamide 791848-00-5P, 3-(2,4'-Dichlorobenzhydryloxy)-N-(2,2,4-trimethylpentan-4-yl)azetidine-1-carboxamide 791848-01-6P, 3-(2,4'-Dichlorobenzhydryloxy)-N-(2-methylbutan-2-yl)azetidine-1-carboxamide 791848-09-4P, 3-[[2-(Trifluoromethyl)-4'-(methylthio)benzhydryl]oxy]-N-(tert-butyl)azetidine-1-carboxamide 791848-10-7P, 3-[[2-(Trifluoromethyl)-4'-(methylthio)benzhydryl]oxy]-N-(isopropyl)azetidine-1-

carboxamide 791848-11-8P, 3-[[2-(Trifluoromethyl)-4'-(
 (methylthio)benzhydryl]oxy]-N-(sec-butyl)azetidine-1-carboxamide
 791848-12-9P, 3-[[2-(Trifluoromethyl)-4'-(
 (methylthio)benzhydryl]oxy]-N-(benzyl)azetidine-1-carboxamide
 791848-16-3P, 3-[[2-(Trifluoromethyl)-4-fluoro-4'-
 chlorobenzhydryl]oxy]-N-(tert-butyl)azetidine-1-carboxamide
 791848-17-4P, 3-[[2-(Trifluoromethyl)-4-fluoro-4'-
 chlorobenzhydryl]oxy]-N-(isopropyl)azetidine-1-carboxamide
 791848-18-5P, 3-[[2-(Trifluoromethyl)-4-fluoro-4'-
 chlorobenzhydryl]oxy]-N-(sec-butyl)azetidine-1-carboxamide
 791848-20-9P, 3-[[2-(Trifluoromethyl)-4-fluoro-4'-
 chlorobenzhydryl]oxy]-N-(benzyl)azetidine-1-carboxamide
 791848-23-2P, 3-[2-(Trifluoromethyl)benzhydryloxy]-N-(tert-
 butyl)azetidine-1-carboxamide 791848-24-3P, 3-[2-
 (Trifluoromethyl)benzhydryloxy]-N-(isopropyl)azetidine-1-carboxamide
 791848-25-4P, 3-[2-(Trifluoromethyl)benzhydryloxy]-N-(sec-
 butyl)azetidine-1-carboxamide 791848-27-6P, 3-[2-
 (Trifluoromethyl)benzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
 791848-31-2P, 3-[[2-(Trifluoromethyl)-4'-(
 (trifluoromethoxy)benzhydryl]oxy)-N-(tert-butyl)azetidine-1-carboxamide
 791848-32-3P, 3-[[2-(Trifluoromethyl)-4'-(
 (trifluoromethoxy)benzhydryl]oxy)-N-(isopropyl)azetidine-1-carboxamide
 791848-33-4P, 3-[[2-(Trifluoromethyl)-4'-(
 (trifluoromethoxy)benzhydryl]oxy)-N-(sec-butyl)azetidine-1-carboxamide
 791848-34-5P, 3-[[2-(Trifluoromethyl)-4'-(
 (trifluoromethoxy)benzhydryl]oxy)-N-(benzyl)azetidine-1-carboxamide
 791848-37-8P 791848-41-4P, 3-[[2-(Trifluoromethyl)-4'-(
 methylbenzhydryl]oxy]-N-(tert-butyl)azetidine-1-carboxamide
 791848-46-9P, 3-[[2-(Trifluoromethyl)-4'-methoxybenzhydryl]oxy]-N-(
 tert-butyl)azetidine-1-carboxamide 791848-49-2P,
 3-[[2-(Trifluoromethyl)-4'-fluorobenzhydryl]oxy]-N-(tert-butyl)azetidine-1-
 carboxamide 791848-51-6P, 3-[[2-(Trifluoromethyl)-4'-
 chlorobenzhydryl]oxy]-N-(allyl)azetidine-1-carboxamide
 791848-56-1P, 3-[[2-(Trifluoromethyl)-4'-(
 (methylsulfonyl)benzhydryl]oxy)-N-(tert-butyl)azetidine-1-carboxamide
 791848-60-7P, 3-[[2-(Trifluoromethyl)-4'-(
 (difluoromethoxy)benzhydryl]oxy)-N-(tert-butyl)azetidine-1-carboxamide
 791848-61-8P, 3-[[2-(Trifluoromethyl)-4'-(
 (difluoromethoxy)benzhydryl]oxy)-N-(sec-butyl)azetidine-1-carboxamide
 791848-62-9P, 3-[[2-(Trifluoromethyl)-4'-(
 (difluoromethoxy)benzhydryl]oxy)-N-(isopropyl)azetidine-1-carboxamide
 791848-64-1P, 3-[[2-(Trifluoromethyl)-4'-(
 (difluoromethoxy)benzhydryl]oxy)-N-(allyl)azetidine-1-carboxamide
 791848-65-2P, 3-[[2-(Trifluoromethyl)-4'-fluorobenzhydryl]oxy]-N-(
 sec-butyl)azetidine-1-carboxamide 791848-66-3P,
 3-[[2-(Trifluoromethyl)-4'-fluorobenzhydryl]oxy]-N-(isopropyl)azetidine-1-
 carboxamide 791848-67-4P 791848-68-5P,
 3-[[2-(Trifluoromethyl)-2'-fluoro-4'-(1-piperidinylomethyl)benzhydryl]ox
 y]-N-(tert-butyl)azetidine-1-carboxamide 791848-69-6P,
 3-[[2-(Trifluoromethyl)-2'-fluorobenzhydryl]oxy]-N-(tert-butyl)azetidine-1-
 carboxamide 791848-70-9P 791848-71-0P
 791848-75-4P 791848-76-5P 791848-78-7P,
 3-[[4-Iodophenyl](2-trifluoromethylphenyl)methoxy]-N-(tert-butyl)azetidine-
 1-carboxamide 791848-79-8P, 3-[[4-Aminocarbonylphenyl](2-
 trifluoromethylphenyl)methoxy]-N-(tert-butyl)azetidine-1-carboxamide
 791848-80-1P, 3-[[4-(Thiophen-2-yl)phenyl][2-
 (trifluoromethyl)phenyl]methoxy]-N-(tert-butyl)azetidine-1-carboxamide
 791848-81-2P, 3-[[4-(3-Pyridinyl)phenyl][2-
 (trifluoromethyl)phenyl]methoxy]-N-(tert-butyl)azetidine-1-carboxamide
 791848-83-4P, 3-[[4-(Morpholin-4-ylmethyl)phenyl][2-
 (trifluoromethyl)phenyl]methoxy]-N-(tert-butyl)azetidine-1-carboxamide
 791848-84-5P, 3-[[4-[(Cyclopropylmethyl)(amino)methyl]phenyl][2-


(trifluoromethyl)phenyl)methoxy]-N-(tert-butyl)azetidine-1-carboxamide
 791848-87-8P, 3-[[4-(4-Pyridyl)phenyl](2-trifluoromethylphenyl)methoxy]-N-tert-butylazetidine-1-carboxamide
 791848-88-9P, 3-[[4-(2,4-Dihydroxypyrimidin-5-yl)phenyl](2-trifluoromethylphenyl)methoxy]-N-tert-butylazetidine-1-carboxamide
 791848-89-0P, 3-[[4-(2-Phenylethenyl)phenyl](2-trifluoromethylphenyl)methoxy]-N-tert-butylazetidine-1-carboxamide
 791848-91-4P, 3-[[2-(Trifluoromethyl)phenyl][4'-(carboxy)phenyl)methoxy]-N-tert-butylazetidine-1-carboxamide
 791848-92-5P 791848-98-1P, (S)-3-[(4-Bromophenyl)(2-trifluoromethylphenyl)methoxy]-N-tert-butylazetidine-1-carboxamide
 791849-02-0P, (R)-3-[(4-Bromophenyl)(2-trifluoromethylphenyl)methoxy]-N-tert-butylazetidine-1-carboxamide
 791849-05-3P, 3-[[4-(4-Methylpiperazin-1-ylmethyl)phenyl][2-(trifluoromethyl)phenyl)methoxy]-N-(tert-butyl)azetidine-1-carboxamide
 791849-08-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of azetidinecarboxamide derivs. for the treatment of CB1 receptor-mediated disorders)


RN 791847-07-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)(2,4-dichlorophenyl)methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 791847-08-0 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)(2,4-dichlorophenyl)methoxy]-N-(2-hydroxy-1,1-dimethylethyl)- (CA INDEX NAME)




RN 791847-09-1 CAPLUS

CN Alanine, N-[[3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-1-azetidiny]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 791847-10-4 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 791847-11-5 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[2-(2-thienyl)ethyl]- (CA INDEX NAME)




RN 791847-12-6 CAPLUS

CN Phenylalanine, N-[[3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-1-azetidiny]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 791847-13-7 CAPLUS

CN Methionine, N-[[3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-1-azetidiny]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 791847-14-8 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 791847-15-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(2,3-dihydro-5-benzofuranyl)methyl]- (CA INDEX NAME)




RN 791847-16-0 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(2,5-dimethyl-3-furanyl)methyl]- (CA INDEX NAME)




RN 791847-17-1 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]- (CA INDEX NAME)



RN 791847-18-2 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)



RN 791847-19-3 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(1R)-1-methylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 791847-20-6 CAPLUS


CN 1-Azetidinecarboxamide, N-[(2-bromo-3-thienyl)methyl]-3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]- (CA INDEX NAME)



RN 791847-21-7 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(1S)-1-methylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 791847-22-8 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-(3-thienylmethyl)- (CA INDEX NAME)




RN 791847-23-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 791847-24-0 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-(2-furanylmethyl)- (CA INDEX NAME)




RN 791847-25-1 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-(3-ethoxypropyl)- (CA INDEX NAME)




RN 791847-26-2 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 791847-27-3 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 791847-29-5 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-(1-phenylpropyl)- (CA INDEX NAME)



RN 791847-30-8 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791847-31-9 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 791847-32-0 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 791847-33-1 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-[(1S)-1-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 791847-34-2 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 791847-35-3 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-hexyl- (CA INDEX NAME)




RN 791847-38-6 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 791847-39-7 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 791847-40-0 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(2,4-dichlorophenyl)methyl]- (CA INDEX NAME)




RN 791847-41-1 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-(2-phenylethyl)- (CA INDEX NAME)



RN 791847-42-2 CAPLUS


CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



RN 791847-43-3 CAPLUS


CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 791847-44-4 CAPLUS


CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 791847-45-5 CAPLUS


CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 791847-46-6 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 791847-47-7 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-(diphenylmethyl)- (CA INDEX NAME)




RN 791847-49-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-(cyclohexylmethyl)- (CA INDEX NAME)




RN 791847-50-2 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-(2-thienylmethyl)-
(CA INDEX NAME)




RN 791847-51-3 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]- (CA INDEX NAME)




RN 791847-52-4 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(2,3-dihydro-5-benzofuranyl)methyl]- (CA INDEX NAME)




RN 791847-53-5 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-3-[bis(4-chlorophenyl)methoxy]- (CA INDEX NAME)




RN 791847-54-6 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]- (CA INDEX NAME)




RN 791847-55-7 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[[2-(2-thienyl)-4-thiazolyl)methyl]- (CA INDEX NAME)




RN 791847-56-8 CAPLUS

CN 1-Azetidinecarboxamide, N-(benzo[b]thien-3-ylmethyl)-3-[bis(4-chlorophenyl)methoxy]- (CA INDEX NAME)




RN 791847-57-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-(3-thienylmethyl)- (CA INDEX NAME)




RN 791847-58-0 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 791847-59-1 CAPLUS

CN 1-Azetidinecarboxamide, N-(benzo[b]thien-2-ylmethyl)-3-[bis(4-chlorophenyl)methoxy]- (CA INDEX NAME)




RN 791847-63-7 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(2-chlorophenyl)methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 791847-64-8 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(2-chlorophenyl)methoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 791847-65-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(2-chlorophenyl)methoxy]-N-(1-methylpropyl)-
(CA INDEX NAME)




RN 791847-66-0 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(2-chlorophenyl)methoxy]-N-propyl- (CA
INDEX NAME)




RN 791847-67-1 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(2-chlorophenyl)methoxy]-N-2-propenyl- (9CI)
(CA INDEX NAME)




RN 791847-68-2 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(2-chlorophenyl)methoxy]-N-butyl- (CA INDEX NAME)




RN 791847-71-7 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(2-chlorophenyl)methoxy]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 791847-73-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(2-chlorophenyl)methoxy]-N-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]- (CA INDEX NAME)




RN 791847-74-0 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(2-chlorophenyl)methoxy]-N-[[2-(1-piperidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 791847-76-2 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(2-chlorophenyl)methoxy]-N-(cyclohexylmethyl)- (CA INDEX NAME)




RN 791847-77-3 CAPLUS

CN 1-Azetidinecarboxamide, N-(benzo[b]thien-3-ylmethyl)-3-[bis(2-chlorophenyl)methoxy]- (CA INDEX NAME)




RN 791847-80-8 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-bromophenyl)methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 791847-81-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-bromophenyl)methoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 791847-82-0 CAPLUS


CN 1-Azetidinecarboxamide, 3-[bis(4-bromophenyl)methoxy]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 791847-83-1 CAPLUS
 CN 1-Azetidinecarboxamide, 3-[bis(4-bromophenyl)methoxy]-N-propyl- (CA INDEX NAME)




RN 791847-84-2 CAPLUS
 CN 1-Azetidinecarboxamide, 3-[bis(4-bromophenyl)methoxy]-N-butyl- (CA INDEX NAME)




RN 791847-87-5 CAPLUS
 CN 1-Azetidinecarboxamide, 3-[bis(4-bromophenyl)methoxy]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 791847-90-0 CAPLUS
 CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-propyl- (CA INDEX NAME)



RN 791847-91-1 CAPLUS
 CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 791847-92-2 CAPLUS
 CN 1-Azetidinecarboxamide, N-butyl-3-[(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791847-93-3 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 791847-94-4 CAPLUS

CN β -Alanine, N-[[3-[(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-1-azetidiny]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 791847-96-6 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-ethyl- (CA INDEX NAME)



RN 791847-97-7 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 791847-98-8 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy]-N-(1,1,3,3-tetramethylbutyl)- (CA INDEX NAME)




RN 791848-00-5 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-(1,1,3,3-tetramethylbutyl)- (CA INDEX NAME)




RN 791848-01-6 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]-N-(1,1-dimethylpropyl)- (CA INDEX NAME)




RN 791848-09-4 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-(methylthio)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-10-7 CAPLUS

CN 1-Azetidinecarboxamide, N-(1-methylethyl)-3-[[4-(methylthio)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-11-8 CAPLUS

CN 1-Azetidinecarboxamide, N-(1-methylpropyl)-3-[[4-(methylthio)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-12-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[[4-(methylthio)phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-(phenylmethyl)- (CA INDEX NAME)




RN 791848-16-3 CAPLUS

CN 1-Azetidinecarboxamide, 3-[[4-(methylthio)phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 791848-17-4 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)[4-fluoro-2-(trifluoromethyl)phenyl]methoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 791848-18-5 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)[4-fluoro-2-(trifluoromethyl)phenyl]methoxy]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 791848-20-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)[4-fluoro-2-(trifluoromethyl)phenyl]methoxy]-N-(phenylmethyl)- (CA INDEX NAME)




RN 791848-23-2 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[phenyl[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-24-3 CAPLUS

CN 1-Azetidinecarboxamide, N-(1-methylethyl)-3-[phenyl[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-25-4 CAPLUS

CN 1-Azetidinecarboxamide, N-(1-methylpropyl)-3-[phenyl[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-27-6 CAPLUS

CN 1-Azetidinecarboxamide, N-(phenylmethyl)-3-[phenyl 2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-31-2 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-(trifluoromethoxy)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-32-3 CAPLUS

CN 1-Azetidinecarboxamide, N-(1-methylethyl)-3-[[4-(trifluoromethoxy)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-33-4 CAPLUS

CN 1-Azetidinecarboxamide, N-(1-methylpropyl)-3-[[4-(trifluoromethoxy)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-34-5 CAPLUS

CN 1-Azetidinecarboxamide, N-(phenylmethyl)-3-[[4-(trifluoromethoxy)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-37-8 CAPLUS

CN 1-Azetidinecarboxamide, 3-[[4-(trifluoromethoxy)phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylpropyl)- (CA INDEX NAME)




RN 791848-41-4 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[(4-methylphenyl)[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-46-9 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[(4-methoxyphenyl)[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-49-2 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[(4-fluorophenyl)[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-51-6 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 791848-56-1 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-(methylsulfonyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-60-7 CAPLUS

CN 1-Azetidinecarboxamide, 3-[[4-(difluoromethoxy)phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 791848-61-8 CAPLUS

CN 1-Azetidinecarboxamide, 3-[[4-(difluoromethoxy)phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 791848-62-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[[4-(difluoromethoxy)phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 791848-64-1 CAPLUS

CN 1-Azetidinecarboxamide, 3-[[4-(difluoromethoxy)phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 791848-65-2 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(4-fluorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-(1-methylpropyl)- (CA INDEX NAME)



RN 791848-66-3 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(4-fluorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 791848-67-4 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(4-fluorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 791848-68-5 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[2-fluoro-4-(1-piperidinylcarbonyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



RN 791848-69-6 CAPLUS


CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[(2-fluorophenyl)[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



RN 791848-70-9 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(S)-(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 791848-71-0 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(R)-(4-chlorophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 791848-75-4 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[(S)-[4-(methylsulfonyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 791848-76-5 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[(R)-[4-


(methylsulfonyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 791848-78-7 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[(4-iodophenyl)(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)




RN 791848-79-8 CAPLUS

CN 1-Azetidinecarboxamide, 3-[[4-(aminocarbonyl)phenyl](2-(trifluoromethyl)phenyl)methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 791848-80-1 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-(2-thienyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-81-2 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-(3-pyridinyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-83-4 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-(4-morpholinylmethyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-84-5 CAPLUS

CN 1-Azetidinecarboxamide, 3-[[4-(1-amino-2-cyclopropylethyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 791848-87-8 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-(4-pyridinyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-88-9 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-89-0 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-(2-phenylethenyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 791848-91-4 CAPLUS

CN Benzoic acid, 4-[[[1-[(1,1-dimethylethyl)amino]carbonyl]-3-azetidinyl]oxy][2-(trifluoromethyl)phenyl]methyl- (CA INDEX NAME)



RN 791848-92-5 CAPLUS


CN 1-Azetidinecarboxamide, 3-[[4-[(diethylamino)carbonyl]phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 791848-98-1 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(S)-(4-bromophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 791849-02-0 CAPLUS


CN 1-Azetidinecarboxamide, 3-[(R)-(4-bromophenyl)(2-(trifluoromethyl)phenyl)methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 791849-05-3 CAPLUS


CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl][2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



RN 791849-08-6 CAPLUS

CN 1-Azetidinecarboxamide, N-(1,1-dimethylethyl)-3-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl][2-(trifluoromethyl)phenyl]methoxy]-, (2E)-2-butenedioate (1:2) (CA INDEX NAME)

CRN 791849-05-3
CMF C28 H37 F3 N4 O2




CM	2
CRN	110-17-8
CMF	C4 H4 O4

Double bond geometry as shown.



IT	791848-82-3P, 3-[[[4-(Chloromethyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-(tert-butyl)azetidine-1-carboxamide RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of azetidinecarboxamide derivs. for the treatment of CB1 receptor-mediated disorders)
RN	791848-82-3 CAPLUS
CN	1-Azetidinecarboxamide, 3-[[[4-(chloromethyl)phenyl][2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




IT 791848-86-7, 3-[(4-Bromophenyl)(2-trifluoromethylphenyl)methoxy]-N-tert-butylazetidine-1-carboxamide
RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of azetidinecarboxamide derivs. for the treatment of
CB1 receptor-mediated disorders)

RN 791848-86-7 CAPLUS

CN 1-Azetidinecarboxamide, 3-[(4-bromophenyl)[2-(trifluoromethyl)phenyl]methoxy]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2004:965053 CAPLUS

DOCUMENT NUMBER: 141:410804

TITLE: Preparation of azetidinecarboxamides for the treatment

INVENTOR(S): Davidson, James Edward Paul; Adams, David Reginald; Bickerdike, Michael John; Fletcher, Allan

PATENT ASSIGNEE(S): Vernalis Research Limited, UK

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096209	A1	20041111	WO 2004-GB1812	20040429
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004233644	A1	20041111	AU 2004-233644	20040429
CA 2524245	A1	20041111	CA 2004-2524245	20040429
EP 1617839	A1	20060125	EP 2004-730286	20040429
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004009959	A	20060425	BR 2004-9959	20040429
CN 1780615	A	20060531	CN 2004-80011755	20040429
JP 2006525297	T	20061109	JP 2006-506193	20040429

NO 2005005655	A	20060131	NO 2005-5655	20051130
IN 2005CN03218	A	20070831	IN 2005-CN3218	20051201
US 20060276452	A1	20061207	US 2006-552574	20060804
PRIORITY APPLN. INFO.:			GB 2003-10057	A 20030501
			WO 2004-GB1812	W 20040429

OTHER SOURCE(S): MARPAT 141:410804

GI




AB The title compds. [I; R1 = aryl; R2 = H, alkyl, aryl; R3 = H, alkyl] useful in the manufacture of a medicament for the treatment of a disorder mediated by CB1 receptors, were prepared E.g., a 2-step synthesis of 3-[bis(4-chlorophenyl)methoxy]-N-(2-propenyl)azetidine-1-carboxamide, starting from 4,4'-dichlorobenzhydrol and 1-(diphenylmethyl)-3-azetidinol, which showed Ki of 285 nM against human CB1 receptor binding, was given.

IT 232599-14-3P 232599-15-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azetidinecarboxamides for the treatment of a disorder mediated by CB1 receptors)

RN 232599-14-3 CAPLUS


CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-2-propenyl- (9CI)
 (CA INDEX NAME)



RN 232599-15-4 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(2R)-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS ON SIN

ACCESSION NUMBER: 2001:78215 CAPLUS

DOCUMENT NUMBER: 134:147488

TITLE: Preparation of azetidine-1-carboxamide derivatives as neuroprotectants

INVENTOR(S): Snape, Mike; Monck, Nathaniel Julius; Fletcher, Allan; Stanhope, Kelly Jean; Mansell, Howard Langham; Nelson, Alan John

PATENT ASSIGNEE(S): Vernalis Research Limited, UK

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007023	A2	20010201	WO 2000-GB2841	20000721
WO 2001007023	A3	20010525		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1212054	A2	20020612	EP 2000-946208	20000721
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
PRIORITY APPLN. INFO.:			GB 1999-17386	A 19990723
			WO 2000-GB2841	W 20000721

OTHER SOURCE(S): MARPAT 134:147488

GI



AB The use of a compound of formula I [wherein: R1 = aryl; R2 = H, alkyl, or aryl; R3 = H or alkyl; groups may be (un)saturated and/or (un)substituted] or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for neuroprotection is disclosed. The compds. are useful for the treatment of cerebral ischemia, central nervous system injury, or eye diseases. Over 40 synthetic examples are given. For instance, etherification of 1-(diphenylmethyl)-3-azetidinol with 4-chlorobenzyl chloride (80%), followed by deprotection-substitution with phosgene and amidation with allylamine (60%), gave title compound II. In a mouse permanent middle cerebral artery occlusion ischemia model, two other compds. I gave significant neuroprotection at 60-100 mg/kg i.p.


IT 232599-14-3P, 3-[Bis(4-chlorophenyl)methoxy]-N-(2-propenyl)azetidine-1-carboxamide 232599-15-4P, (R)-3-[Bis(4-chlorophenyl)methoxy]-N-(2-hydroxypropyl)azetidine-1-carboxamide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of azetidinecarboxamides as neuroprotectants)

RN 232599-14-3 CAPLUS


CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-2-propenyl- (9CI)
(CA INDEX NAME)



RN 232599-15-4 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(2R)-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:487269 CAPLUS

DOCUMENT NUMBER: 131:116144

TITLE: Azetidinedicarboxamide derivatives for treating CNS disorders

INVENTOR(S): Shepherd, Robin Gerald; Adams, David Reginald; Bodkin, Corinna Dagmar; Cliffe, Ian Anthony; Mansell, Howard Langham; Monck, Nathaniel Julius

PATENT ASSIGNEE(S): Cerebrus Limited, UK; Shepherd, Joy Miriam

SOURCE: PCI Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937612	A1	19990729	WO 1999-GB219	19990122
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, ID, TG			
AU 9922874	A	19990809	AU 1999-22874	19990122
EP 1049672	A1	20001108	EP 1999-902658	19990122
EP 1049672	B1	20030917		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002501045	T	20020115	JP 2000-528536	19990122
AT 250027	T	20031015	AT 1999-902658	19990122
PT 1049672	T	20040227	PT 1999-902658	19990122
ES 2207171	T3	20040516	ES 1999-902658	19990122
US 6403574	B1	20020611	US 2001-600628	20010917
PRIORITY APPLN. INFO.:			GB 1998-1500	A 19980123
			GB 1998-24457	A 19981106
			WO 1999-GB219	W 19990122

OTHER SOURCE(S): MARPAT 131:116144

GI




AB 3-(4-Chlorobenzoyloxy)-1-diphenylmethylazetidine, prepared in 80% yield from 1-diphenylmethyl-3-azetidinol and 4-chlorobenzyl chloride, was treated with phosgene and then allylamine to give 60% I (R = 4-chlorobenzyl) (II). Among the 7 other title compds. similarly prepared were I [R = 3,4-dichlorobenzyl, 3-, 4-trifluoromethylbenzyl, 4-fluorobenzyl, bis(4-chlorophenyl)methyl]. The title compds. may be used for treatment of CNS disorders such as anxiety and epilepsy. Compound II exhibited a binding affinity, $\text{IC}_{50}(\mu\text{M})$, to the GABAA receptor of 56 and an ED of 30 mg/Kg for anxiolytic activity in the rat.

IT 232599-14-3P 232599-15-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anxiolytic and anticonvulsant activity of azetidinecarboxamides)

RN 232599-14-3 CAPLUS


CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-2-propenyl- (9CI)
(CA INDEX NAME)



RN 232599-15-4 CAPLUS

CN 1-Azetidinecarboxamide, 3-[bis(4-chlorophenyl)methoxy]-N-[(2R)-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

28.69

337.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.00

-4.00

FILE 'STNGUIDE' ENTERED AT 18:17:37 ON 01 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 28, 2008 (20080328/UP).

=>